The Experience of the Fight Against COVID-19 in Clinical Laboratory Departments from Chengdu, China

OBJECTIVE: In order to fight against coronavirus disease 2019 (COVID-19) better and to share our experience as a reference for clinical laboratory departments. METHODS: This was a retrospective study conducted in the clinical laboratory department of Chengdu Women’s and Children’s Central Hospital i...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Qin, Liu, Chenggui, Xu, Jian, Song, Peipei, Yang, Shuzhe, Zhang, Qin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8505680/
https://www.ncbi.nlm.nih.gov/pubmed/34675712
http://dx.doi.org/10.2147/RMHP.S323605
_version_ 1784581584427417600
author Wang, Qin
Liu, Chenggui
Xu, Jian
Song, Peipei
Yang, Shuzhe
Zhang, Qin
author_facet Wang, Qin
Liu, Chenggui
Xu, Jian
Song, Peipei
Yang, Shuzhe
Zhang, Qin
author_sort Wang, Qin
collection PubMed
description OBJECTIVE: In order to fight against coronavirus disease 2019 (COVID-19) better and to share our experience as a reference for clinical laboratory departments. METHODS: This was a retrospective study conducted in the clinical laboratory department of Chengdu Women’s and Children’s Central Hospital in Chengdu, China, from April 2020 to January 2021. The number of nucleic acid and antibody testing specimens of suspected COVID-19 cases was analyzed. The key points of suspected-case sample processing and detection in the clinical laboratory department were summarized. The laboratory was directly involved in the sample processing and testing of suspected cases, the release of reports, and the transfer of specimens to the fever clinic. RESULTS: The number of COVID-19 nucleic acid test specimens in our laboratory ranged from 102 to 2170 per day, and the number of antibody test specimens ranged from 24 to 391 per day. There were four main considerations in the treatment and detection of suspected-case specimens in the clinical laboratory: biosafety management in clinical laboratory departments, measures to ensure the health of the staff, the eight time points for processing suspected-case samples (turn-around time), and key points for the detection of suspected case specimens. CONCLUSION: The laboratory developed a protective process for COVID-19 antibody and nucleic acid detection during the pandemic. At present, the detection of COVID-19 antibodies and nucleic acids in the clinical laboratory department is orderly, and there have been no cases of laboratory infection.
format Online
Article
Text
id pubmed-8505680
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-85056802021-10-20 The Experience of the Fight Against COVID-19 in Clinical Laboratory Departments from Chengdu, China Wang, Qin Liu, Chenggui Xu, Jian Song, Peipei Yang, Shuzhe Zhang, Qin Risk Manag Healthc Policy Perspectives OBJECTIVE: In order to fight against coronavirus disease 2019 (COVID-19) better and to share our experience as a reference for clinical laboratory departments. METHODS: This was a retrospective study conducted in the clinical laboratory department of Chengdu Women’s and Children’s Central Hospital in Chengdu, China, from April 2020 to January 2021. The number of nucleic acid and antibody testing specimens of suspected COVID-19 cases was analyzed. The key points of suspected-case sample processing and detection in the clinical laboratory department were summarized. The laboratory was directly involved in the sample processing and testing of suspected cases, the release of reports, and the transfer of specimens to the fever clinic. RESULTS: The number of COVID-19 nucleic acid test specimens in our laboratory ranged from 102 to 2170 per day, and the number of antibody test specimens ranged from 24 to 391 per day. There were four main considerations in the treatment and detection of suspected-case specimens in the clinical laboratory: biosafety management in clinical laboratory departments, measures to ensure the health of the staff, the eight time points for processing suspected-case samples (turn-around time), and key points for the detection of suspected case specimens. CONCLUSION: The laboratory developed a protective process for COVID-19 antibody and nucleic acid detection during the pandemic. At present, the detection of COVID-19 antibodies and nucleic acids in the clinical laboratory department is orderly, and there have been no cases of laboratory infection. Dove 2021-10-07 /pmc/articles/PMC8505680/ /pubmed/34675712 http://dx.doi.org/10.2147/RMHP.S323605 Text en © 2021 Wang et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Perspectives
Wang, Qin
Liu, Chenggui
Xu, Jian
Song, Peipei
Yang, Shuzhe
Zhang, Qin
The Experience of the Fight Against COVID-19 in Clinical Laboratory Departments from Chengdu, China
title The Experience of the Fight Against COVID-19 in Clinical Laboratory Departments from Chengdu, China
title_full The Experience of the Fight Against COVID-19 in Clinical Laboratory Departments from Chengdu, China
title_fullStr The Experience of the Fight Against COVID-19 in Clinical Laboratory Departments from Chengdu, China
title_full_unstemmed The Experience of the Fight Against COVID-19 in Clinical Laboratory Departments from Chengdu, China
title_short The Experience of the Fight Against COVID-19 in Clinical Laboratory Departments from Chengdu, China
title_sort experience of the fight against covid-19 in clinical laboratory departments from chengdu, china
topic Perspectives
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8505680/
https://www.ncbi.nlm.nih.gov/pubmed/34675712
http://dx.doi.org/10.2147/RMHP.S323605
work_keys_str_mv AT wangqin theexperienceofthefightagainstcovid19inclinicallaboratorydepartmentsfromchengduchina
AT liuchenggui theexperienceofthefightagainstcovid19inclinicallaboratorydepartmentsfromchengduchina
AT xujian theexperienceofthefightagainstcovid19inclinicallaboratorydepartmentsfromchengduchina
AT songpeipei theexperienceofthefightagainstcovid19inclinicallaboratorydepartmentsfromchengduchina
AT yangshuzhe theexperienceofthefightagainstcovid19inclinicallaboratorydepartmentsfromchengduchina
AT zhangqin theexperienceofthefightagainstcovid19inclinicallaboratorydepartmentsfromchengduchina
AT wangqin experienceofthefightagainstcovid19inclinicallaboratorydepartmentsfromchengduchina
AT liuchenggui experienceofthefightagainstcovid19inclinicallaboratorydepartmentsfromchengduchina
AT xujian experienceofthefightagainstcovid19inclinicallaboratorydepartmentsfromchengduchina
AT songpeipei experienceofthefightagainstcovid19inclinicallaboratorydepartmentsfromchengduchina
AT yangshuzhe experienceofthefightagainstcovid19inclinicallaboratorydepartmentsfromchengduchina
AT zhangqin experienceofthefightagainstcovid19inclinicallaboratorydepartmentsfromchengduchina